(Albany, US) September 10, 2026- DelveInsight’s “Pulmonary Hypertension-associated Interstitial Lung Disease Market Insights, Epidemiology, and Market Forecast – 2036” report delivers an in-depth understanding of Pulmonary Hypertension-associated Interstitial Lung Disease, historical and forecasted epidemiology, and the Pulmonary Hypertension-associated Interstitial Lung Disease market trends in the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.

Download DelveInsight’s comprehensive report to explore PH-ILD market trends, pipeline analysis @ https://www.delveinsight.com/sample-request/pulmonary-hypertension-associated-with-interstitial-lung-disease-ph-ild-market

Key Takeaways from the Pulmonary Hypertension-associated Interstitial Lung Disease Market Report

• On September 02, 2026, Pulmovant Inc. initiated a Phase 2, open-label, multi-center clinical study to evaluate the safety and tolerability of inhaled mosliciguat in participants with pulmonary hypertension associated with interstitial lung disease (PH-ILD) on a background of inhaled treprostinil.
• On September 02, 2026, Liquidia Technologies Inc. conducted a phase 3 study is to find out if L606 is safe and if it helps people with high blood pressure in the lungs (pulmonary hypertension) caused by interstitial lung disease (PH-ILD, WHO Group 3). One of the main ways the study will check this is by seeing if people can walk further in six minutes (called the “six-minute walk test”). Another important (secondary) goal is to see how long it takes for PH-ILD to get worse while people are taking L606. One way the study will measure this is by looking at the distance people walk at different times in the study on different doses of L606.
• As of 2025, the total diagnosed prevalent population of PH-ILD across the 7MM is estimated at nearly 182,000, reflecting the significant burden of the disease.
• Beyond PH-ILD, the broader diagnosed prevalent population of ILD in the 7MM was significantly higher, reaching approximately more than 1 million cases in 2025, underscoring the large pool of patients at risk of developing associated pulmonary hypertension.
• In the year 2025, the United States represented the largest share of the PH-ILD market, with nearly 83,000 diagnosed prevalent cases, supported by advanced diagnostic infrastructure and higher clinical awareness.
• In 2025, EU4 and the UK together contributed approximately 70,000 cases of PH-ILD with the United Kingdom representing the largest individual European segment with nearly 18,000 of PH-ILD diagnosed cases.
• Japan accounted for approximately 29,000 diagnosed prevalent cases of PH-ILD in 2025, representing a stable and clinically significant patient base in the Asian market.
• Gender-specific analysis in the United States for 2025 shows a slightly higher prevalence in males, with approximately 43,000 cases, compared to nearly 40,000 cases in females.
• The leading PH-ILD Companies such as Pharmosa BioPharm, Liquidia Corporation, Insmed, Roivant Sciences, Pulmovant, and others.
• Promising PH-ILD Therapies such as TYVASO/TYVASO DPI (treprostinil), TPIP, INOpulse, Inhaled Treprostinil, Riociguat (Adempas, BAY63-2521), Bardoxolone methyl, and others.

Access DelveInsight’s in-depth PH-ILD market analysis and strategic insights today! Click here for more @ Pulmonary Hypertension-associated Interstitial Lung Disease Treatment Market Size

Pulmonary Hypertension Associated with Interstitial Lung Disease Overview

PH-ILD refers to a wide range of lung conditions, many of which involve scarring or inflammation in the thin layer of tissue between the air sacs and nearby blood vessels. This delicate region, known as the interstitium, is just micrometers thick but plays a vital role by maintaining the structure of the alveoli and enabling smooth oxygen transfer into the bloodstream. Several factors can increase the risk of developing PH-ILD. Chronic smoking and long-term exposure to environmental or occupational toxins can damage the lung tissue, contributing to inflammation and fibrosis that elevate pulmonary artery pressure.

Pulmonary Hypertension-associated Interstitial Lung Disease Epidemiology Segmentation in the 7MM

• Total PH-ILD Diagnosed Prevalent Cases
• PH-ILD Type-specific Diagnosed Prevalent Cases
• PH-ILD Type-specific Diagnosed Prevalent Cases
• Total PH-ILD Diagnosed Prevalent Cases
• PH-ILD Gender-specific Diagnosed Prevalent Cases

Download the report to understand which factors are driving PH-ILD epidemiology trends @ Pulmonary Hypertension associated Interstitial Lung Disease Prevalence

PH-ILD Approved Therapies

• Treprostinil (YUTREPIA): Liquidia Corporation

YUTREPIA is a dry powder inhalation formulation of treprostinil sodium, a prostacyclin mimetic designed for the treatment of PAH. Delivered through a single-use, handheld inhaler, each capsule contains treprostinil sodium blended with carefully selected excipients: L-leucine, polysorbate 80, sodium chloride, sodium citrate, and trehalose.

PH-ILD Pipeline Analysis

• Treprostinil liposomal (L606): Pharmosa BioPharm/Liquidia Corporation

L606 is a liposomal formulation of treprostinil, with liposome particle sizes ranging from 110–140 nm, suspended in a sodium citrate–bicarbonate buffer. This advanced formulation is engineered to enhance drug stability and prolong systemic circulation by protecting treprostinil from rapid degradation and clearance. The liposomal encapsulation enables a sustained pulmonary release, allowing for more consistent drug exposure over time, while minimizing peaks and troughs that may lead to side effects.

Discover the future of PH-ILD treatments @ Pulmonary Hypertension-associated Interstitial Lung Disease Market Drivers and Barriers

Pulmonary Hypertension-Associated Interstitial Lung Disease Treatment Market

The PH-ILD treatment landscape is shifting from supportive care to targeted, disease-modifying approaches that address vascular remodeling, fibrosis, and inflammation. Traditional strategies, including ILD management and lung transplantation, offer limited impact on long-term outcomes, highlighting the need for more effective therapies. New drug classes with lung-targeted mechanisms are advancing PH-ILD treatment. Inhaled prostacyclins like treprostinil have enhanced exercise capacity, setting the stage for next-generation agents such as Mosliciguat (sGC activator), H1614 (HA synthesis inhibitor), and RT234 (inhaled PDE5 inhibitor). These candidates aim to deliver broader benefits—beyond vasodilation—by incorporating anti-fibrotic and anti-inflammatory effects, marking a shift toward disease-modifying approaches.

Pulmonary Hypertension-Associated Interstitial Lung Disease Market Outlook

The Pulmonary Hypertension-Associated Interstitial Lung Disease Market Outlook is evolving, driven by high unmet clinical need, increasing disease recognition, and the progressive nature of cardiopulmonary impairment associated with the condition. While no curative therapies currently exist, growing adoption of supportive care, oxygen therapy, and targeted pulmonary vasodilators, along with advancements in understanding disease pathophysiology, are expected to support market growth and improve long-term patient management outcomes.

Scope of the Pulmonary Hypertension-Associated Interstitial Lung Disease Market Report

• Coverage- 7MM
• Study Period- 2022-2036
• PH-ILD Companies- Pharmosa BioPharm, Liquidia Corporation, Insmed, Roivant Sciences, Pulmovant, and others.
• PH-ILD Therapies- TYVASO/TYVASO DPI (treprostinil), TPIP, INOpulse, Inhaled Treprostinil, Riociguat (Adempas, BAY63-2521), Bardoxolone methyl, and others.
• PH-ILD Therapeutic Assessment: PH-ILD current marketed and PH-ILD emerging therapies
• PH-ILD Market Dynamics: PH-ILD market drivers and PH-ILD market barriers
• PH-ILD Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
• PH-ILD Unmet Needs, KOL’s views, Analyst’s views, PH-ILD Market Access and Reimbursement

From PH-ILD market size to emerging drugs-find it all in our latest report. Read now! @ Pulmonary Hypertension associated Interstitial Lung Disease Ongoing Clinical Trials Analysis

Table of Content

1. Key Insights
2. Report Introduction
3. Pulmonary Hypertension-Associated Interstitial Lung Disease Market Overview at a Glance
4. Pulmonary Hypertension-Associated Interstitial Lung Disease Epidemiology and Market Methodology
5. Executive Summary
6. Key Events
7. Pulmonary Hypertension-Associated Interstitial Lung Disease: Disease Background and Overview
8. Pulmonary Hypertension-Associated Interstitial Lung Disease Epidemiology and Patient Population
9. Patient Journey
10. Pulmonary Hypertension-Associated Interstitial Lung Disease Marketed Drugs
11. Pulmonary Hypertension-Associated Interstitial Lung Disease Emerging Drugs
12. Pulmonary Hypertension-Associated Interstitial Lung Disease: Market Analysis
13. Key Opinion Leaders’ Views
14. Pulmonary Hypertension-Associated Interstitial Lung Disease SWOT Analysis
15. Pulmonary Hypertension-Associated Interstitial Lung Disease Unmet Needs
16. Pulmonary Hypertension-associated Interstitial Lung Disease Market Access and Reimbursement
17. Appendix
18. DelveInsight Capabilities
19. Disclaimer

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/pulmonary-hypertension-associated-with-interstitial-lung-disease-ph-ild-market